Schering Corporation

Merck Sharp + Dohme Corp.

Yan Wang

Jonathan A Pachter

Leonard G Presta

Mohan Srinivasan

Peter Brams

Denise Leah Williams

Robert Greenberg

Judith Hailey

Diane Feingersh

Yaolin Wang

Walter Robert Bishop

Leonard Presta

Ming Liu

Siu-Long Yao

Cynthia Seidel-Dugan

Brian DerHua Lu

Chen Zong

Mohamed H Ladha

Brian Der-Hua Lu

This invention relates to methods for evaluating the efficacy of an IGF1R inhibitor, such as an anti-IGF1R antibody, for the treatment of an Ewing's sarcoma tumor by determining the level of tumoral glucose metabolism. Tumoral glucose metabolism is determining at an early point in the treatment regimen by any of several methods known in the art including FDG-PET/CT scan.

FDG-pet evaluation of Ewing's sarcoma sensitivity

The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.

Neutralizing human anti-IGFR antibody

The present invention provides combinations including a binding composition, such as an anti-IGFR1 antibody, in association with a chemotherapeutic agent. Methods for using the combinations to treat medical conditions, such as cancer, are also provided.

Anti-IGFR1 antibody therapeutic combinations

The present invention provides methods for identifying patients whose cancers are likely to be responsive to IGF1R inhibitory anti-cancer therapy along with methods for treating such patients. Patients identified by a method of the present invention can be treated with any of several known IGF1R inhibitory agents including antibodies, small molecule inhibitors and anti-sense nucleic acids.

Biomarkers for pre-selection of patients for anti-IGF1R therapy

The present invention includes isolated nucleic acids encoding fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). Also included are methods of using and producing the antibodies of the invention.

Growing community of inventors

Scotch Plains, NJ, United States of America

Yan Wang